Add BrightSurf on Google Email

International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy

The Strategies for Management of Anti-Retroviral Therapy (SMART) trial found that participants on continuous antiretroviral therapy had significantly lower risk of disease progression compared to those on episodic therapy. The study also revealed increased risks of cardiovascular, kidney, and liver diseases in participants on the drug ...

Relationship between incarceration and race disparities in US HIV rates explored

Research examines how drug policy affects incarceration rates and HIV infection levels among African Americans, who make up 40% of those incarcerated and 50% of new HIV diagnoses. The study calls for further research on the corrections system's impact on HIV risk and recommends investigating specific components of drug policy.

SourceYale University·JournalJournal of Health Care for the Poor and Underserved·DateDec 12, 2005

HIV-infected adults in Botswana respond positively to ARV therapy public treatment program

The study found that more than 95% of HIV-infected people in resource-poor nations can benefit from combination ARV treatment, leading to improved CD4 counts, decreased viral load, and weight gain. The results underscore the importance of monitoring drug tolerability and toxicity to ensure patients' quality of life and adherence rates.

SourceHarvard T.H. Chan School of Public Health·JournalJAIDS Journal of Acquired Immune Deficiency Syndromes·DateNov 4, 2005

Drug trials & the media

A study examining media reports on the closure of HIV drug trials in Cambodia and Cameroon found that many articles failed to identify primary sources or provided inaccurate information. The researchers stress that both the media and trial organisers have a responsibility to provide accurate information during periods of controversy.

SourceBMC (BioMed Central)·JournalBMC International Health and Human Rights·DateAug 24, 2005

New approach has potential to treat latent HIV infection

A new approach using valproic acid has shown promise in reducing latent HIV infection by 75% in three out of four patients. The researchers suggest that a staged treatment process, starting with standard antiretroviral regimens and then targeting latent viral infection with HDAC inhibitors, could lead to the cure of HIV.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 11, 2005

A much-needed shot in the arm for HIV vaccine development

The Global HIV/AIDS Vaccine Enterprise has launched a scientific strategic plan to address major roadblocks in HIV vaccine development and proposes an innovative collaborative model for researchers worldwide. The plan aims to harness new opportunities, including an expanded pipeline of HIV vaccine candidates and improved animal models.

SourcePLOS·JournalPLOS Medicine·DateJan 18, 2005